Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma

Abstract

G protein-coupled receptors (GPCRs), the largest human gene family, are important regulators of signaling pathways. However, knowledge of their genetic alterations is limited. In this study, we used exon capture and massively parallel sequencing methods to analyze the mutational status of 734 GPCRs in melanoma. This investigation revealed that one family member, GRM3, was frequently mutated and that one of its mutations clustered within one position. Biochemical analysis of GRM3 alterations revealed that mutant GRM3 selectively regulated the phosphorylation of MEK, leading to increased anchorage-independent growth and migration. Melanoma cells expressing mutant GRM3 had reduced cell growth and cellular migration after short hairpin RNA–mediated knockdown of GRM3 or treatment with a selective MEK inhibitor, AZD-6244, which is currently being used in phase 2 clinical trials. Our study yields the most comprehensive map of genetic alterations in the GPCR gene family.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Effects of GRM3 alterations on cell growth and MEK phosphorylation.
Figure 2: GRM3 mutations increase migration in vitro and in vivo.
Figure 3: Expression of mutant GRM3 provides cell proliferation and survival signals in melanoma.
Figure 4: Melanoma cell lines expressing GRM3 mutants show increased sensitivity to inhibition of MEK by AZD-6244.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

  2. 2

    Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

  3. 3

    Dorsam, R.T. & Gutkind, J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7, 79–94 (2007).

  4. 4

    Lee, H.J., Wall, B. & Chen, S. G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res 21, 415–428 (2008).

  5. 5

    Flower, D.R. Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. Acta 1422, 207–234 (1999).

  6. 6

    Porreca, G.J. et al. Multiplex amplification of large sets of human exons. Nat. Methods 4, 931–936 (2007).

  7. 7

    Prickett, T.D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127–1132 (2009).

  8. 8

    Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).

  9. 9

    Ng, P.C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003).

  10. 10

    Pollock, P.M. et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34, 108–112 (2003).

  11. 11

    Davies, M.A. et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 15, 7538–7546 (2009).

  12. 12

    Aronica, E. et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur. J. Neurosci. 17, 2106–2118 (2003).

  13. 13

    Brabet, I. et al. Comparative effect of L–CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37, 1043–1051 (1998).

  14. 14

    Nishi, N., Odagaki, Y. & Koyama, T. Pharmacological characterization of metabotropic glutamate receptor-mediated high-affinity GTPase activity in rat cerebral cortical membranes. Br. J. Pharmacol. 130, 1664–1670 (2000).

  15. 15

    Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).

  16. 16

    Bian, D. et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res. 64, 4209–4217 (2004).

  17. 17

    Yu, J.J. et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc. Natl. Acad. Sci. USA 106, 2635–2640 (2009).

  18. 18

    McDermott, D.F. et al. Double-blind randomized phase 2 study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol. 26, 2178–2185 (2008).

  19. 19

    Rinehart, J. et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456–4462 (2004).

  20. 20

    Palavalli, L.H. et al. Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat. Genet. 41, 518–520 (2009).

  21. 21

    Viloria, C.G. et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 69, 4926–4934 (2009).

  22. 22

    Wei, X. et al. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol. Cancer Res. 8, 1513–1525 (2010).

Download references

Acknowledgements

We thank S. Gutkind, J. Cronin, H. Abaan, P. Cruz, J. Mullikin, N. Hansen and members of the US National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program for generating the sequence data analyzed here. We thank S. Hoogstraten-Miller and I. Ginty for assistance with the mouse experiments and S. Anderson for assistance with FACS analysis. This work was supported by the Intramural Research Programs of the National Human Genome Research Institute and National Cancer Institute, US National Institutes of Health, USA. Grant support was also provided by the University of Texas MD Anderson Cancer Center Melanoma Informatics, Tissue Resource and Pathology Core and the Melanoma Specialized Programs of Research Excellence (P50 CA93459). M.A.D. is supported by funding from the Melanoma Research Alliance, the American Society of Clinical Oncology and the MD Anderson Physician-Scientist Program. A.M. is supported by the Intramural Research program of the National Institute of Dental and Craniofacial Research, NIH.

Author information

T.D.P., I.C.-N., X.W., E.H.M. and Y.S. designed the study. K.S.-H., M.A.D., J.E.G. and S.A.R. collected and analyzed the melanoma samples. X.W., I.C.-N., J.K.T., J.G., P.F.C. and J.C.L. analyzed the genetic data. T.D.P., A.M., J.J. and V.W. produced and analyzed the functional data. All authors contributed to the final version of the paper.

Correspondence to Yardena Samuels.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6, 8 and 9, Supplementary Tables 1–11 and Supplementary Note. (PDF 2481 kb)

Supplementary Table 7

MIP probes used for GPCR capture (XLS 1346 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Prickett, T., Wei, X., Cardenas-Navia, I. et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 43, 1119–1126 (2011). https://doi.org/10.1038/ng.950

Download citation

Further reading